AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 161 min read$PSNL

Chen Richard sold $1.5M of PSNL

Chen Richard (President and CMO) sold 100,000 shares of Personalis, Inc. (PSNL) at $15.15 ($1.52M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chen Richard
Published Jul 16, 2026, 1:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
high confidence
Mentioned
$PSNL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The disclosed sale provides a datapoint on insider behavior but does not, by itself, change the company’s disclosed fundamentals or guidance.

02

Market read

For PSNL traders, the main takeaway is insider selling magnitude ($1.515M) with 10b5-1 context, which typically reduces interpretive weight.

03

What to watch

Traders may want to compare with prior insider transactions and total insider ownership changes to judge whether this is part of a broader selling trend.

Relevance 5/10Novelty 5/10Timing: immediately following the 2026-07-15 insider sale disclosure on SEC EDGAR

Background

The article is an SEC Form 4 insider transaction for Personalis, Inc. (PSNL) filed on 2026-07-15, reporting a scheduled open-market sale by the company’s President and CMO.

Company-level read

Ticker impact

$PSNLNeutralHigh confidence
Context

Personalis insider Chen Richard (President and CMO) sold 100,000 shares on 2026-07-15 under a 10b5-1 plan, worth $1.515M.

Expected impact

Likely minimal, unless accompanied by other negative disclosures or unusual selling patterns.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement; the article provides no new operating, regulatory, or financial datapoints beyond the sale details.

Market effects

Sector

No sector-level implications; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Personalis, Inc.

    US-listed company whose insider transaction is disclosed on SEC Form 4.

  • insider
    Chen Richard

    President and CMO who sold 100,000 shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PSNL insider trading history →

Related articles

OCT 6
$PSNLMed

Personalis, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger with Tempus AI, Inc., a Nevada corporation, Aviary Development, Inc.…

Personalis, Inc. (PSNL) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on July 20, 2026, Personalis, Inc., a Delaware corporation (“ Personalis ” or the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Tempus AI, Inc., a Nevada corporation (“ Tempus ” or “ Par

SEC EDGAR 8-K2 min
OCT 6
$PSNLHigh

Why is Personalis stock sliding today?

Personalis (PSNL) stock fell 2.8% after BTIG downgraded it to Neutral, removing the $16.25 price target. The analyst believes the Tempus AI acquisition will close at the agreed price, with little chance of improvement. BTIG also concluded that the board prioritized deal speed over a higher bid, despite interest from Merck. The S&P 500 and other indices rose, but Personalis' decline was stock-specific.

investing.com1 min
SEP 27
$PSNLHighAI 9/10

Personalis CFO and COO Aaron Tachibana sells $47,540 in stock

Personalis CFO Aaron Tachibana sold 2,931 shares at $16.22 each, totaling $47,540, to cover tax obligations. Tempus AI agreed to acquire Personalis for $1.5B, offering $16.25 per share, a 6% premium. Needham downgraded Personalis to Hold, raised its target to $17, and reiterated a Buy rating for Tempus AI with a $75 target. Personalis received UK regulatory clearance for its NeXT Personal Dx test.

investing.com2 min
SEP 5
$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min
AUG 27
$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

simplywall.st2 min